5月于深圳成立
6月首次提交PCT申请
7月MVR- T3011病毒骨架构建
8月完成符合 GMP标准的CMC 研究
7月MVR-T3011 IT 获得中国IND 批准
8月澳大利亚OGTR临床许可证批准
4月MVR-T3011 IT中国临床I期FPI
5月MVR-T3011获得美国IND许可
6月MVR-T3011 IT澳洲临床I期FPI
8月MVR-T3011 IT大中华区区域权益授予上海医药
5月MVR-T3011 IT 中国临床II期FPI
6月MVR-T3011 IT 美国临床II期FPI
7月中试生产线(深圳)正式投产
8月MVR-T3011 IV获得中国IND批准
8月MVR-C5252获得美国IND许可
8月MVR-T3011 IV 美国临床I期FPI
3月MVR-T3011 IV 中国临床I期FPI
4月在美国与罗氏合作开发MVR-T3011 IT和MEK抑制剂联合疗法
7月与华润生物医药于大中华区域联合开发MVR-C5252
8月MVR-C5252(针对脑胶质瘤)获美国FDA “孤儿药”认定
3月Cytiva 达成战略合作,共同开发外泌体新型疗法
3月MVR-C5252 获得中国IND 批准
9 月 苏州商业化生产基地启动
1月MVR-EX103北美区域化妆品权益授予某MNC
4月MVR-EX103获INCI命名
CEO at Ankyra Therapeutics, Former CMO at Replimune
Global leading authority on local tumor immunotherapy and oncolytic viruses
Lead the successful phase III trial of T-VEC
Medical Oncologist, Memorial Sloan Kettering Cancer Center
Medical Oncologist, Banner MD Anderson Cancer Center at Banner Gateway Medical Center
Medical Oncologist, Neuro-oncologist, and
Deputy Director of the Center for Cancer
Immunotherapy, Duke Cancer Institute
Joseph Regenstein Distinguished Srvc. Prof., Biological Sciences Division, Microbiology, the University of Chicago
Daniel K. Ludwig Distinguished Srvc. Professor of Radiation & Cellular Oncology
The University of Chicago
James A. Elkins Jr. Professor in the Life Sciences, Department of Molecular Biology
Princeton University
Distinguished Professor of Pediatrics, Professor of Microbiology, Medicine and Neurosurgery
The University of Alabama at Birmingham
IQVIA大中华区业务拓展副总裁
前零氪科技执行副总裁
IEPMA ICH M14 专家工作组成员
前CDE首席科学家